Biotech Company
ProMIS Neurosciences Inc. (TSX:PMN, OTCQB:ARFXF, Forum) on Tuesday released operational and financial results for the three months ended March 31, 2019. The Company highlighted its $2.1 million private placement and its identification of several promising drug candidates.
For more on this, click
here.
ProMIS is expanding its portfolio of opportunities in neurodegenerative diseases and was
recently featured in an InvestorIdeas.com article that covered some of these drug candidates and the Company’s work to treat a root cause of Parkinson's disease.
FULL DISCLOSURE: ProMIS Neurosciences Inc. is a client of Stockhouse Publishing.